Immunogenicity and protective efficacy of prime-boost immunization in mice vaccinated with live and inactivated influenza A (H5N1) vaccines

Avian influenza A (H1N1) in humans is characterized by severe clinical manifestation and high mortality. The main drawback of current human H5N1 vaccines is related to low immunogenicity. Prime-boost vaccination is considered as an effective approach to enhance vaccine immunogenicity. The aim of thi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	I. Losev, G. Petukhova, I. Isakova-Sivak, L. Rudenko
Formato:	article
Lenguaje:	RU
Publicado:	Sankt-Peterburg : NIIÈM imeni Pastera 2019
Materias:	influenza vaccines influenza prime-boost immunization vaccination live attenuated influenza vaccine influenza virus а (h5n2) Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/37f3fc5a738741eea67975ee79e4b01b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:37f3fc5a738741eea67975ee79e4b01b
record_format	dspace
spelling	oai:doaj.org-article:37f3fc5a738741eea67975ee79e4b01b2021-11-22T07:09:52ZImmunogenicity and protective efficacy of prime-boost immunization in mice vaccinated with live and inactivated influenza A (H5N1) vaccines2220-76192313-739810.15789/2220-7619-2019-1-67-75https://doaj.org/article/37f3fc5a738741eea67975ee79e4b01b2019-05-01T00:00:00Zhttps://www.iimmun.ru/iimm/article/view/618https://doaj.org/toc/2220-7619https://doaj.org/toc/2313-7398Avian influenza A (H1N1) in humans is characterized by severe clinical manifestation and high mortality. The main drawback of current human H5N1 vaccines is related to low immunogenicity. Prime-boost vaccination is considered as an effective approach to enhance vaccine immunogenicity. The aim of this study was to compare immune response and protective efficacy of diverse prime-boost immunization protocols: 1) prime and boost with live influenza vaccine (LAIV) А/17/Turkey/Turkey/05/133 (H5N2); 2) prime with LAIV А/17/Turkey/Turkey/05/133 (H5N2) followed by boost with inactivated influenza vaccine (IIV) “Orniflu” (H5N1). Both vaccination protocols were found to increase serum antibody level against homologous and heterologous influenza A virus strains. In particular, serum HAI antibodies were significantly elevated solely after LAIV/LAIV vaccination. A more sensitive sandwich ELISA assay revealed that serum virus-specific IgG antibody levels were significantly increased after both vaccination protocols as well as after a single LAIV or IIV vaccination. Both LAIV and IIV boost increased titers of serum IgG specific against unrelated influenza A (H5N1) strains: homologous A/NIBRG-23 (clade 2.2), A/Indonesia (clade 2.1) and, to a lesser extent, against clade 1 virus A/ Vietnam and even against heterologous А/New York (H1N1). Single LAIV vaccination was also able to induce antibody responses against all strains examined, though to a lesser degree as compared with either prime-boost protocols. However, amount of splenic CD8+ Тcells specific to homologous influenza A virus strain was solely observed after LAIV/IIV vaccination. Moreover, both LAIV and IIV boosting effect demonstrated high protection level against lethal challenge with А (H1N1) WT virus and significantly decreased lung viral titer compared to control group. Furthermore, both regimens resulted in lung virus clearance after non-lethal challenge with clade 1, 2.1 or 2.2 influenza А (H5N1). In conclusion, we demonstrated that both LAIV/LAIV and LAIV/IIV regimens were able to induce cross-clade A (H5N1) response and that prime-boost immunization was a promising approach to improve immunogenicity of influenza A (H5N1) virus vaccine.I. LosevG. PetukhovaI. Isakova-SivakL. RudenkoSankt-Peterburg : NIIÈM imeni Pasteraarticleinfluenza vaccinesinfluenzaprime-boost immunizationvaccinationlive attenuated influenza vaccineinfluenza virus а (h5n2)Infectious and parasitic diseasesRC109-216RUInfekciâ i Immunitet, Vol 9, Iss 1, Pp 67-75 (2019)
institution	DOAJ
collection	DOAJ
language	RU
topic	influenza vaccines influenza prime-boost immunization vaccination live attenuated influenza vaccine influenza virus а (h5n2) Infectious and parasitic diseases RC109-216
spellingShingle	influenza vaccines influenza prime-boost immunization vaccination live attenuated influenza vaccine influenza virus а (h5n2) Infectious and parasitic diseases RC109-216 I. Losev G. Petukhova I. Isakova-Sivak L. Rudenko Immunogenicity and protective efficacy of prime-boost immunization in mice vaccinated with live and inactivated influenza A (H5N1) vaccines
description	Avian influenza A (H1N1) in humans is characterized by severe clinical manifestation and high mortality. The main drawback of current human H5N1 vaccines is related to low immunogenicity. Prime-boost vaccination is considered as an effective approach to enhance vaccine immunogenicity. The aim of this study was to compare immune response and protective efficacy of diverse prime-boost immunization protocols: 1) prime and boost with live influenza vaccine (LAIV) А/17/Turkey/Turkey/05/133 (H5N2); 2) prime with LAIV А/17/Turkey/Turkey/05/133 (H5N2) followed by boost with inactivated influenza vaccine (IIV) “Orniflu” (H5N1). Both vaccination protocols were found to increase serum antibody level against homologous and heterologous influenza A virus strains. In particular, serum HAI antibodies were significantly elevated solely after LAIV/LAIV vaccination. A more sensitive sandwich ELISA assay revealed that serum virus-specific IgG antibody levels were significantly increased after both vaccination protocols as well as after a single LAIV or IIV vaccination. Both LAIV and IIV boost increased titers of serum IgG specific against unrelated influenza A (H5N1) strains: homologous A/NIBRG-23 (clade 2.2), A/Indonesia (clade 2.1) and, to a lesser extent, against clade 1 virus A/ Vietnam and even against heterologous А/New York (H1N1). Single LAIV vaccination was also able to induce antibody responses against all strains examined, though to a lesser degree as compared with either prime-boost protocols. However, amount of splenic CD8+ Тcells specific to homologous influenza A virus strain was solely observed after LAIV/IIV vaccination. Moreover, both LAIV and IIV boosting effect demonstrated high protection level against lethal challenge with А (H1N1) WT virus and significantly decreased lung viral titer compared to control group. Furthermore, both regimens resulted in lung virus clearance after non-lethal challenge with clade 1, 2.1 or 2.2 influenza А (H5N1). In conclusion, we demonstrated that both LAIV/LAIV and LAIV/IIV regimens were able to induce cross-clade A (H5N1) response and that prime-boost immunization was a promising approach to improve immunogenicity of influenza A (H5N1) virus vaccine.
format	article
author	I. Losev G. Petukhova I. Isakova-Sivak L. Rudenko
author_facet	I. Losev G. Petukhova I. Isakova-Sivak L. Rudenko
author_sort	I. Losev
title	Immunogenicity and protective efficacy of prime-boost immunization in mice vaccinated with live and inactivated influenza A (H5N1) vaccines
title_short	Immunogenicity and protective efficacy of prime-boost immunization in mice vaccinated with live and inactivated influenza A (H5N1) vaccines
title_full	Immunogenicity and protective efficacy of prime-boost immunization in mice vaccinated with live and inactivated influenza A (H5N1) vaccines
title_fullStr	Immunogenicity and protective efficacy of prime-boost immunization in mice vaccinated with live and inactivated influenza A (H5N1) vaccines
title_full_unstemmed	Immunogenicity and protective efficacy of prime-boost immunization in mice vaccinated with live and inactivated influenza A (H5N1) vaccines
title_sort	immunogenicity and protective efficacy of prime-boost immunization in mice vaccinated with live and inactivated influenza a (h5n1) vaccines
publisher	Sankt-Peterburg : NIIÈM imeni Pastera
publishDate	2019
url	https://doaj.org/article/37f3fc5a738741eea67975ee79e4b01b
work_keys_str_mv	AT ilosev immunogenicityandprotectiveefficacyofprimeboostimmunizationinmicevaccinatedwithliveandinactivatedinfluenzaah5n1vaccines AT gpetukhova immunogenicityandprotectiveefficacyofprimeboostimmunizationinmicevaccinatedwithliveandinactivatedinfluenzaah5n1vaccines AT iisakovasivak immunogenicityandprotectiveefficacyofprimeboostimmunizationinmicevaccinatedwithliveandinactivatedinfluenzaah5n1vaccines AT lrudenko immunogenicityandprotectiveefficacyofprimeboostimmunizationinmicevaccinatedwithliveandinactivatedinfluenzaah5n1vaccines
_version_	1718417910327672832

Immunogenicity and protective efficacy of prime-boost immunization in mice vaccinated with live and inactivated influenza A (H5N1) vaccines

Ejemplares similares